Table 2.
Demographic and clinical data of healthy controls and Parkinson’s disease cohorts.
| HCs (n = 420) | sPD (n = 250) | GBA-PD (n = 23) | LRRK2-PD (n = 27) | P value | |
|---|---|---|---|---|---|
| Sex (% males) | 52.14% | 58.40% | 73.91% | 37.02 | 0.03** |
| Age (y), Mean ± SD | 58.77 ± 16.09 | 65.92 ± 11.77 | 58.83 ± 11.8 | 63.41 ± 11.79 | <0.005** |
| Arterial hypertension, n (%) | 139 (33%) | 104 (42%) | 8 (35%) | 8 (30%) | 0.17 |
| Diabetes, n (%) | 52 (12%) | 45 (18%) | 1 (4%) | 2 (7%) | 0.08 |
| Hyperlipidemia, n (%) | 57 (14%) | 47 (19%) | 2 (9%) | 6 (22%) | 0.19 |
| Age of onset (y), mean ± SD | – | 56.60 ± 11.95 | 48.39 ± 8.87 | 51.65 ± 12.86 | 0.007* |
| Disease duration (y), mean ± SD | – | 8.9 ± 6.23 | 10.67 ± 7.69 | 11.81 ± 7.06 | <0.05* |
| Hoehn & Yahr, mean ± SD | – | 2.26 ± 1.22 | 2.5 ± 0.96 | 1.9 ± 2.4 | 0.16 |
| LEDD, mean ± SD | – | 764.74 ± 470.14 | 694.25 ± 408.76 | 797.46 ± 579.46 | 0.86 |
HCs healthy controls, LEDD levodopa equivalent daily dose, sPD sporadic Parkinson’s disease patients, GBA-PD GBA-associated Parkinson’s disease patients, LRRK2-PD LRRK2-associated Parkinson’s disease patients, SD standard deviation.
*p<0.05 **p<0.005.